Active substance
Piperacillin
- SFDA 4
- US FDA 4
- Safety 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| PIPRIL VIAL 1G+SOLVENT 10ML | 1 g | Injection · Intravenous use | 1 Vial | SAR 26.30 | NCE · Prescription | CYANAMID LEDERLE | Withdrawn by regulatory authority · Not Marketed |
| PIPRIL VIAL 2G+SOLVENT 20ML | 2 g | Injection · Intravenous use | 1 Vial | SAR 51.95 | NCE · Prescription | CYANAMID LEDERLE | Withdrawn by regulatory authority · Not Marketed |
| PIPRIL VIAL 4G | 4 g | Injection · Intravenous use | 1 Vial | SAR 89.35 | NCE · Prescription | CYANAMID LEDERLE | Withdrawn by regulatory authority · Not Marketed |
| PIPRIL VIAL 6G | 6 g | Injection · Intravenous use | 1 Vial | SAR 130.15 | NCE · Prescription | CYANAMID LEDERLE | Withdrawn by regulatory authority · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PIPERACILLIN | EQ 2GM BASE/VIAL; EQ 3GM BASE/VIAL; EQ 4GM BASE/VIAL | injectable · injection | ACS DOBFAR SPA | Prescription | 14 Nov 2003 |
| PIPERACILLIN | EQ 40GM BASE/VIAL | injectable · injection | ACS DOBFAR SPA | Prescription | 12 Jul 2004 |
| PIPRACIL | EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 3GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 4GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 40GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | WYETH PHARMS INC | Discontinued | 29 Dec 1981 |
| PIPRACIL | EQ 2GM BASE/VIAL; EQ 3GM BASE/VIAL; EQ 4GM BASE/VIAL | injectable · injection | WYETH PHARMS INC | Discontinued | 13 Oct 1987 |
Safety signals and safety-related labeling changes
- US FDA 3 Dec 2024 ZOSYN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 3 Dec 2024 ZOSYN IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 30 Sep 2021 PRAC signal: Haemophagocytic lymphohistiocytosis
Action for MAH: update of the product information: Yes - EMA PRAC 9 Apr 2021 PRAC signal: Haemophagocytic lymphohistiocytosis
Action for MAH: update of the product information: No
Combinations containing Piperacillin
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.